Topic Review
Viroids
Viroids are a group of infectious plant lncRNAs that are composed of RNA genomes and replicate by using the host enzymatic activities.
  • 1.7K
  • 30 Oct 2020
Topic Review
Virion Structure of SARS-CoV-2 and Viral Inflammation
COVID-19 is an epidemic infection created by SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2). SARS-CoV-2 has a single-stranded, positive-sense RNA genome with 29,891 nucleotides and 38% G + C content, encoding 9860 amino acids. Human coronaviral inflammation induces the clinical symptoms of fever, cough, and shortness of breath.
  • 456
  • 25 Nov 2022
Topic Review
Viral Vectors
Viral vectors can generate high levels of recombinant protein expression providing the basis for modern vaccine development. A large number of different viral vector expression systems have been utilized for targeting viral surface proteins and tumor-associated antigens.
  • 420
  • 23 Apr 2021
Topic Review
Viral Vector-Based Gene Therapy
Gene therapy is a technique involving the modification of an individual’s genes for treating a particular disease. The key to effective gene therapy is an efficient carrier delivery system. Viral vectors that have been artificially modified to lose their pathogenicity are used widely as a delivery system, with the key advantages of their natural high transduction efficiency and stable expression. With decades of development, viral vector-based gene therapies have achieved promising clinical outcomes. Long-term gene therapy involves the administration of a specific genetic material (i.e., DNA or RNA) via a carrier, referred to as a “delivery vector,” which facilitates the entry of the foreign genetic material into target cells. The delivery vectors are of two types: viral vectors and non-viral vectors. The commonly used viral vectors are adeno-associated viruses (AAVs), adenoviruses (Ads), or lentiviruses (LVs).
  • 297
  • 09 May 2023
Topic Review
Viral Transmissibility of SARS-CoV-2
The emergence of coronavirus disease 2019 (COVID-19), caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a global health calamity unprecedented in the modern world. The disease spread worldwide, and to date, there have been over 230 million confirmed cases of COVID-19, including approximately 4.7 million deaths. Mutant variants of the virus have raised concerns about additional pandemic waves and threaten to reverse our progress thus far to limit the spread of the virus. 
  • 450
  • 27 Apr 2022
Topic Review
Viral Interactions with Adaptor-Protein Complexes
Numerous viruses hijack cellular protein trafficking pathways to mediate cell entry or to rearrange membrane structures thereby promoting viral replication and antagonizing the immune response. Adaptor protein complexes (AP), which mediate protein sorting in endocytic and secretory transport pathways, are one of the conserved viral targets. We present here different mechanisms of viral interference with AP complexes and the functional consequences that allow for efficient viral propagation and evasion of host immune defense. The best described examples are interactions of human immunodeficiency virus and human herpesviruses with AP complexes. Several other viruses, like Ebola, Nipah, and SARS-CoV-2, are pointed out as high priority disease-causative agents supporting the need for deeper understanding of virus-AP interplay which can be exploited in the design of novel antiviral therapies
  • 447
  • 13 Jun 2021
Topic Review
Viral Infection-Mediated Pulmonary Epigenetics
Respiratory viral infections can trigger chronic lung diseases. Number of studies have shown that respiratory viral infection causes epigenetic changes, which refer to genetic alterations that affect gene expression without any mutational genetic changes.
  • 202
  • 12 Jul 2023
Topic Review
Viral Equine Encephalitis
Neurological disorders represent an important sanitary and economic threat for the equine industry worldwide. Among nervous diseases, viral encephalitis is of growing concern, due to the emergence of arboviruses and to the high contagiosity of herpesvirus-infected horses. The nature, severity and duration of the clinical signs could be different depending on the etiological agent and its virulence. However, definite diagnosis generally requires the implementation of combinations of direct and/or indirect screening assays in specialized laboratories. The equine practitioner, involved in a mission of prevention and surveillance, plays an important role in the clinical diagnosis of viral encephalitis. The general management of the horse is essentially supportive, focused on controlling pain and inflammation within the central nervous system, preventing injuries and providing supportive care. Despite its high medical relevance and economic impact in the equine industry, vaccines are not always available and there is no specific antiviral therapy. In this review, the major virological, clinical and epidemiological features of the main neuropathogenic viruses inducing encephalitis in equids in Europe, including rabies virus (Rhabdoviridae), Equid herpesviruses (Herpesviridae), Borna disease virus (Bornaviridae) and West Nile virus (Flaviviridae), as well as exotic viruses, will be presented.
  • 1.2K
  • 29 Oct 2020
Topic Review
Viral Ejection Proteins
Genes encoding ejection proteins are commonly found in Podoviridae phages that infect Gram-negative bacteria, including Enterobacteriaceae, Mycobacteria, Pseudomonadaceae, and Cyanobacteria.
  • 444
  • 11 Mar 2022
Topic Review
Views on Vaccination against COVID-19 Virus
Mass immunization of the citizens of the Republic of Serbia began in January 2021. Information on the significance, manner, advantages and consequences of this process was intensively distributed through all communication channels, with the media playing a key role. According to the data of the official institutions for the public health of Serbia, by July 2021 the lowest percentage of vaccinated population was among those between the ages of 18 and 24—only 15% of this demographic had received the vaccine by this point.
  • 501
  • 08 Dec 2021
  • Page
  • of
  • 51